EHA at a glance
Join LucidQuest for a concise EHA 2025 preview, focusing on must-see sessions and defining trends in hematology, including breakthrough therapies and the newest uses of AI in clinical practice.
📅 Build your schedule around the topics that interest you. 📥 Download the EHA 2025_Preview_by_LucidQuest
Dive deeper
Key Topics From EHA 2025 Scientific Presentations
Leukemia
-
Cyclophosphamide delivers 73% ORR and superior MRD clearance over methotrexate in LGL.
-
GAIA/CLL13: BTK–VEN (GIV) 5-year PFS 81% in fit CLL, confirming time-limited regimens.
-
Haplo vs mismatched-MUD transplants post-AML/ALL/MDS show equal 4-year OS ≈ 50%. ⚔️
Myeloma
-
MIDAS multi-omics refines risk; hypoxia signature flags poor-prognosis MM.
-
Trispecific ISB 2001 and CELMoD combos yield deep responses in heavily pre-treated RRMM.
-
MRD-guided REMNANT intensifies frontline gains. 🔬
Lymphoma
-
Acimtamig + Allo-NK posts high ORR in r/r cHL.
-
MRD negativity via PhasED-Seq predicts DLBCL survival.
-
Pelabresib + ruxolitinib improves MF fibrosis and anemia. 🛡️
Transplant / GVHD
-
Target-dose ATG cuts CMV and speeds reconstitution.
-
Fecal microbiotherapy (MaaT013) rescues GI-aGVHD after ruxolitinib.
-
Axatilimab shows promise in chronic GVHD. 🏥
AML / MDS
-
Oral decitabine/cedazuridine + VEN matches IV outcomes.
-
Menin inhibitors (ziftomenib, revumenib) achieve high CRc/MRD-neg in NPM1/KMT2A AML.
-
DAC+HAAG beats 7+3 in adverse-risk AML for MRD and 2-year OS. ⚡️
Autoimmune Cytopenias
-
Avatrombopag sustains platelets in pediatric ITP.
-
Sovleplenib (Syk) revives refractory AIHA.
-
Rilzabrutinib (BTK-i) boosts ITP responses. 🌱
Bone Marrow Failure / PNH
-
Iptacopan, pegcetacoplan, crovalimab secure transfusion-free control.
-
Hetrombopag + CsA elevates NSAA response.
-
Luspatercept eases anemia in older NSAA. 💉
Classical Hodgkin Lymphoma (cHL)
-
PET-adapted protocols maintain PFS/OS with lower late toxicity.
-
Nivo-AVD delivers near-universal metabolic responses in frontline, while BBG salvage readies patients for transplant. 🔥
Artificial Intelligence and Machine Learning at EHA 2025
AI_Diagnostics
-
Flow-cytometry and RNA-seq models classify AML, T-ALL, mastocytosis, neutropenia with high accuracy. 🤖
Prognostic ML
-
Multivariate algorithms outperform IPSS-R in MDS and integrate genomics for AML/MPN risk. 📊
Digital Pathology
-
CIF mapping standardises fibrosis/blast counts in BMT slides across centres. 🖥️
Therapy Predict
-
ML forecasts HMA response in MDS, CAR-T toxicity, and asciminib benefit in CML. 🧩
Bleeding Risk AI
-
Models flag AML/ITP hemorrhage risk and evaluate VWD/AIHA drug efficacy. 🩺
Explainable AI
-
SmartCytoFlow 2.0 delivers GPT-4o rationale-based outputs to boost clinician trust. 💡
Access Tech
-
Smartphone AI screens hemoglobinopathies in low-resource settings, widening early detection. 🌍
📅 Build your schedule around the topics that interest you.
📥 Download the EHA 2025_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.